Pear therapeutics announces inclusion of reset® and reset-o® on the january 2023 florida medicaid preferred drug list

Boston--( business wire )-- pear therapeutics, inc. (nasdaq: pear), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (pdts), today announced the inclusion of its pdts reset® and reset-o® on the january 2023 florida medicaid preferred drug list (pdl). reset and reset-o, the only fda-authorized pdts for the treatment of substance use disorder and opioid use disorder, respectively, have been added to the florida medicaid pdl, effective january 1, 2023.
PEAR Ratings Summary
PEAR Quant Ranking